About: A simple protein-based surrogate neutralization assay for SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A simple protein-based surrogate neutralization assay for SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A simple protein-based surrogate neutralization assay for SARS-CoV-2
Creator	Drebot, Michael Li, Zhijie Mubareka, Samira Gingras, Anne-Claude Durocher, Yves Drews, Steven Mcgeer, Allison Ostrowski, Mario Rini, James Dupuis Ii, Alan Mcdonough, Kathleen Wood, Heidi Wang, Jenny Budylowski, Patrick Abe, Kento Barrios-Rodiles, Miriam Colwill, Karen Girardin, Roxie Gommerman, Jennifer Rathod, Bhavisha Samavarchi-Tehrani, Payman Samson, Reuben Valcourt, Emelissa
Source	BioRxiv
abstract	Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a humoral immune response to the virus within a few weeks of infection, but the duration of this response and how it correlates with clinical outcomes has not been completely characterized. Of particular importance is the identification of immune correlates of infection that would support public health decision-making on treatment approaches, vaccination strategies, and convalescent plasma therapy. While ELISA-based assays to detect and quantitate antibodies to SARS-CoV-2 in patient samples have been developed, the detection of neutralizing antibodies typically requires more demanding cell-based viral assays. Here, we present a safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike protein receptor binding domain (RBD) with its receptor, angiotensin converting-enzyme 2 (ACE2). The assay serves as a surrogate neutralization assay and is performed on the same platform and in parallel with an enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against the RBD, enabling a direct comparison. The results obtained with our assay correlate with those of two viral based assays, a plaque reduction neutralization test (PRNT) that uses live SARS-CoV-2 virus, and a spike pseudotyped viral-vector-based assay.
has issue date	2020-08-24(xsd:dateTime)
bibo:doi	10.1101/2020.07.10.197913
has license	biorxiv
sha1sum (hex)	4293bcdcc6f936eaba2f734503525493463ccfc3
schema:url	https://doi.org/10.1101/2020.07.10.197913
resource representing a document's title	A simple protein-based surrogate neutralization assay for SARS-CoV-2
schema:publication	bioRxiv
resource representing a document's body	covid:4293bcdcc6f936eaba2f734503525493463ccfc3#body_text
is schema:about of	named entity 'assays' named entity 'assays' named entity 'samples' named entity 'assay' named entity 'efficient' named entity 'platform' named entity 'SARS-CoV-2' named entity 'neutralizing antibodies' named entity 'SARS-CoV-2' named entity 'surrogate' named entity 'WEEKS' named entity 'SPIKE' named entity 'DOMAIN' named entity 'HAVE' named entity 'PLAQUE REDUCTION NEUTRALIZATION TEST' named entity 'SUPPORT' named entity 'PROTEIN' named entity 'INFECTED' named entity 'ON TREATMENT' named entity 'ASSAY' named entity 'DIRECT' named entity 'COMPARISON' named entity 'RECEPTOR' named entity 'SAFE' named entity 'PUBLIC HEALTH' named entity 'DECISION-MAKING' named entity 'PATIENTS' named entity 'live' named entity 'detection' named entity 'developed' named entity 'infection' named entity 'correlate' named entity 'plasma' named entity 'serum' named entity 'Most' named entity 'completely' named entity 'immune' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'parallel' named entity 'public health' named entity 'enzyme-linked immunosorbent assay' named entity 'convalescent plasma therapy' named entity 'SARS-CoV-2' named entity 'receptor' named entity 'humoral immune response' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2 virus' named entity 'SARS-CoV-2' named entity 'block' named entity 'cytopathic effect' named entity 'protein' named entity 'DMEM' named entity 'sodium bicarbonate' named entity 'Addgene' named entity 'enzyme' named entity 'PBS' named entity 'Fab' named entity 'SARS-CoV' named entity 'virus' named entity 'antibody' named entity 'recombinantly' named entity 'serum'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software